Interactive

FEATURED VIDEO

Image

FDA Risk vs. Benefit: The Drug Safety Debate After 50 Years

Length: 11:10

Why thalidomide shows that drug safety is not a black-and-white issue. A former FDA official explains why thalidomide was brought back. And patient and consumer groups debate risk tolerance and the need for incentives to create new treatments.

View

More Videos

eLEARNING WHITEPAPER

eLEARNING WHITEPAPER FEATURE

Building Bridges to Innovation 2017

Commissioned for the 4th BioCentury China Healthcare Summit (Nov. 14-15, 2017, Shanghai), this exclusive report discusses the latest trends shaping the biopharma industry in China.

 Based on a survey of industry leaders, the report details: